All In MedTech

Device Trial Radar · NCT07258069

Study On Histoacryl Used For Embolization Of Middle Meningeal Artery (MMA) In Chronic Subdural Hematoma (CSDH)

Observational, Prospective, Multicenter Study On Histoacryl Used For Embolization Of Middle Meningeal Artery (MMA) In Chronic Subdural Hematoma (CSDH) (HARMONY)

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

178

Planned (sponsor's estimate)

Start

Apr 10, 2026

Primary completion

Dec 2026

Study completion Aug 2027

Sponsor

Lead sponsor
Aesculap AGNot on our public-company list
Sponsor type
Industry
First posted
Dec 2, 2025

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to proof the effectiveness of Histoacryl® on preventing recurrence or progression of subdural hematoma after embolization of the middle meningeal artery.

Conditions

  • Subdural Hematoma
  • Subdural Hematoma, Chronic

Interventions

  • Histoacryl®Device

    Histoacryl® is used by direct needle puncture, transcatheter approach, or transendoscopic approach in vascular embolization for the described purposes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence or progression of subdural hematomaTime frame: within 3 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Kokura Memorial Hospital

    Fukuoka, Kitakyushu-city, Japan · Not yet recruiting

  • Ohara HealthCare Foundation Kurashiki Central Hospital

    Okayama, Kurashiki, Japan · Not yet recruiting

  • Shimizu Hospital

    Kyoto, Nishikyo-ku, Japan · Recruiting

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.